These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 27810689)

  • 21. Effect of ketoconazole on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor teneligliptin: an open-label study in healthy white subjects in Germany.
    Nakamaru Y; Hayashi Y; Sekine M; Kinoshita S; Thompson J; Kawaguchi A; Davies M; Jürgen Heuer H; Yamazaki H; Akimoto K
    Clin Ther; 2014 May; 36(5):760-9. PubMed ID: 24726088
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats.
    Oguma T; Kuriyama C; Nakayama K; Matsushita Y; Yoshida K; Kiuchi S; Ikenaga Y; Nakamaru Y; Hikida K; Saito A; Arakawa K; Oka K; Ueta K; Shiotani M
    J Pharmacol Sci; 2015 Apr; 127(4):456-61. PubMed ID: 25892328
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial.
    Kadowaki T; Inagaki N; Kondo K; Nishimura K; Kaneko G; Maruyama N; Nakanishi N; Iijima H; Watanabe Y; Gouda M
    Diabetes Obes Metab; 2017 Jun; 19(6):874-882. PubMed ID: 28177187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations.
    Fukuda-Tsuru S; Anabuki J; Abe Y; Yoshida K; Ishii S
    Eur J Pharmacol; 2012 Dec; 696(1-3):194-202. PubMed ID: 23022337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of teneligliptin added to metformin in Chinese patients with type 2 diabetes mellitus inadequately controlled with metformin: A phase 3, randomized, double-blind, placebo-controlled study.
    Ji L; Li L; Ma J; Li X; Li D; Meng B; Lu W; Sun J; Liu Y; Takayanagi G; Wang Y
    Endocrinol Diabetes Metab; 2021 Apr; 4(2):e00222. PubMed ID: 33855222
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Teneligliptin-associated bullous pemphigoid in an elderly man with diabetes.
    Guliani A; Bishnoi A; Aggarwal D; Parsad D
    Postgrad Med J; 2018 Nov; 94(1117):662-663. PubMed ID: 30317183
    [No Abstract]   [Full Text] [Related]  

  • 27. Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, placebo-controlled, parallel-group comparative study.
    Kadowaki T; Inagaki N; Kondo K; Nishimura K; Kaneko G; Maruyama N; Nakanishi N; Gouda M; Iijima H; Watanabe Y
    Diabetes Obes Metab; 2018 Feb; 20(2):453-457. PubMed ID: 28786530
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin.
    Miya A; Nakamura A; Cho KY; Kawata S; Nomoto H; Nagai S; Sugawara H; Taneda S; Tsuchida K; Omori K; Yokoyama H; Takeuchi J; Aoki S; Kurihara Y; Atsumi T; Miyoshi H
    J Diabetes Investig; 2021 Aug; 12(8):1395-1399. PubMed ID: 33325645
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relation Between Hypoglycemia and Glycemic Variability in Type 2 Diabetes Patients with Insulin Therapy: A Study Based on Continuous Glucose Monitoring.
    Uemura F; Okada Y; Torimoto K; Tanaka Y
    Diabetes Technol Ther; 2018 Feb; 20(2):140-146. PubMed ID: 29293363
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Teneligliptin, a Chemotype Prolyl-Thiazolidine-Based Novel Dipeptidyl Peptidase-4 Inhibitor with Insulin Sensitizing Properties.
    Kutoh E; Wada A; Terayama S
    Clin Drug Investig; 2016 Oct; 36(10):809-18. PubMed ID: 27352309
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship of Eating Patterns and Metabolic Parameters, and Teneligliptin Treatment: Interim Results from Post-marketing Surveillance in Japanese Type 2 Diabetes Patients.
    Kadowaki T; Haneda M; Ito H; Sasaki K; Hiraide S; Matsukawa M; Ueno M
    Adv Ther; 2018 Jun; 35(6):817-831. PubMed ID: 29777520
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preventive effect of ipragliflozin on nocturnal hypoglycemia in patients with type 2 diabetes treated with basal-bolus insulin therapy: An open-label, single-center, parallel, randomized control study.
    Okajima F; Nagamine T; Nakamura Y; Hattori N; Sugihara H; Emoto N
    J Diabetes Investig; 2017 May; 8(3):341-345. PubMed ID: 27762088
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of switching to teneligliptin from other dipeptidyl peptidase-4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease.
    Kitada M; Ogura Y; Nitta K; Fujii M; Kanasaki K; Konishi K; Iida Y; Nakagawa A; Koya D
    J Diabetes Investig; 2019 May; 10(3):706-713. PubMed ID: 30136384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of teneligliptin in Japanese patients with type 2 diabetes mellitus: a pooled analysis of two Phase III clinical studies.
    Kadowaki T; Marubayashi F; Yokota S; Katoh M; Iijima H
    Expert Opin Pharmacother; 2015 May; 16(7):971-81. PubMed ID: 25861982
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Teneligliptin : expectations for its pleiotropic action.
    Morishita R; Nakagami H
    Expert Opin Pharmacother; 2015 Feb; 16(3):417-26. PubMed ID: 25597385
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor, Improves Early-Phase Insulin Secretion in Drug-Naïve Patients with Type 2 Diabetes.
    Ito R; Fukui T; Hayashi T; Osamura A; Ohara M; Hara N; Higuchi A; Yamamoto T; Hirano T
    Drugs R D; 2015 Sep; 15(3):245-51. PubMed ID: 26224337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of teneligliptin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.
    Ji L; Ma J; Lu W; Liu J; Zeng J; Yang J; Li W; Zhang X; Xiao X; Takayanagi G; Wang Y
    J Diabetes Investig; 2021 Apr; 12(4):537-545. PubMed ID: 32810383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Teneligliptin: a review in type 2 diabetes.
    Scott LJ
    Clin Drug Investig; 2015 Nov; 35(11):765-72. PubMed ID: 26475720
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Assessment of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Glucocorticoid-induced Diabetes by Continuous Glucose Monitoring.
    Yata Y; Hosojima M; Kabasawa H; Ishikawa T; Kaseda R; Iino N; Suzuki Y; Saito A; Narita I
    Intern Med; 2017 Oct; 56(19):2555-2562. PubMed ID: 28883231
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Study of the Efficacy of Uptitrating Teneligliptin Dose from Standard Dose (20 mg) to High Dose (40 mg) in Patients with Type II Diabetes Mellitus.
    Panikar V; Joshi S; Tiwaskar M; Bhondve A; Nasikkar N; Walawalkar S; Sachdev I; Panikar K; Modh K; Kulkarni P; Medidar R; Tuteja H; Mansoori S
    J Assoc Physicians India; 2022 Jul; 70(7):11-12. PubMed ID: 35833400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.